mAb Quality Assurance &
GMP Compliance
mAb Quality Assurance & GMP Compliance
Phase-appropriate quality systems for monoclonal antibody programs —
from clinical batch disposition and change control through process validation,
comparability assessments, and BLA-stage QA readiness.
Phase-appropriate quality systems for monoclonal antibody programs — from clinical batch disposition and change control through process validation, comparability assessments, and BLA-stage QA readiness.
Clinical through commercial QA support mAb QA Program Scope
Supplier & Vendor QA
Cell Bank Qualification
Raw Material QA
Quality Agreements
SCN Impact Reviews
Manufacturing Operations
Batch Record Review
Deviation & CAPA
Change Control
Process Validation
Product Quality & Release
Batch Release Strategy
Comparability Packages
Stability Governance
PQR Inputs
mAb Quality Assurance Quality Systems That Support Biologics Manufacturing Reality
DES Pharma supports mAb quality assurance programs from clinical development through commercial readiness and post-approval lifecycle management. Effective mAb quality systems go beyond GMP compliance documentation — they need to support batch disposition, change assessment, comparability planning, process validation, continued process verification, stability oversight, and vendor management in ways that reflect how biologics manufacturing actually operates.
Our teams connect QA decisions to cell banking, upstream and downstream process control, analytical strategy, raw material qualification, and release testing, helping sponsors build quality systems that are phase-appropriate, technically defensible, and practical to execute. We support batch record review, deviation and CAPA oversight, comparability assessments for site, scale, process, or cell line changes, supplier qualification, and quality agreements for critical materials and fill-finish operations.
All work is grounded in core biologics requirements under 21 CFR Parts 600 and 610, component and container controls under 21 CFR 211.84, FDA lifecycle process validation principles, and ICH comparability guidance.
Quality Priorities
Quality Priorities for Monoclonal
Antibody Programs
A useful mAb QA strategy keeps attention on the quality systems that most directly affect product consistency, patient safety, and lifecycle flexibility. For monoclonal antibodies, that usually means building quality oversight around process consistency, product-related variants, comparability after change, raw material control, stability, and release readiness. DES Pharma helps clients align those priorities with the actual operating model of the program, whether the product is in early clinical supply or approaching commercial launch.
Comparability Planning
Structured comparability programs for cell line, process, site, and scale changes — designed to satisfy ICH Q5E expectations and support regulatory submissions for both clinical amendments and BLA supplements.
Batch Release Structures
Release frameworks that integrate analytical results, manufacturing review, stability data, and disposition rationale — supporting both phase-appropriate clinical lot release and the more complex commercial batch disposition process.
Stability Governance
Stability program oversight connecting protocol design, data review, trending, and shelf-life strategy for drug substance and drug product across clinical and commercial stages per ICH Q5C.
Process Validation & CPV
Quality oversight for process validation through PPQ and into continued process verification — providing monitoring frameworks that satisfy FDA's lifecycle validation expectations for biological products.
Supplier & Raw Material QA
Qualification programs for CDMOs, fill-finish partners, raw material vendors, and testing labs — including quality agreement support, component testing oversight, and supplier change notification management.
Quality Oversight & Governance
QA structures that support both compliance and practical execution — from phase-appropriate quality plans in early development through inspection-ready GMP systems for commercial biologics manufacturing.
QA Services
mAb Quality Assurance Services
Across Three Workstreams
QA Services mAb Quality Assurance Services Across Three Workstreams
Our mAb QA consulting is organized around the three systems that most directly influence GMP compliance and regulatory readiness — vendor and supplier quality, manufacturing operations, and product release.
Supplier Qualification & Material Quality Oversight
Cell bank qualification, vendor qualification, quality agreements, and incoming material review for critical mAb manufacturing inputs.
- Qualification of cell bank storage, handling, and traceability systems for mAb programs
- Vendor qualification for media, feed components, buffers, resins, filters, and single-use assemblies
- Quality agreements for critical raw materials, process consumables, and outsourced biologics operations
- Incoming material review aligned with component testing, approval, and release requirements
- Assessment of supplier change notifications for impact on process consistency and product quality
- Qualification oversight for fill-finish partners, packaging suppliers, and testing laboratories
- Review of material traceability, CoA documentation, and deviation escalation pathways
- Support for risk-based classification of high-impact and long lead-time materials
Manufacturing Operations QA & Process Oversight
Batch record review, deviation management, change control, process validation, and CPV for mAb upstream, downstream, and fill-finish operations.
- Batch record review for upstream culture, harvest, purification, UF/DF, formulation, and fill-finish steps
- Deviation, CAPA, and investigation support linked to product quality impact and manufacturing history
- Change control review for cell line, scale, equipment, site, resin, raw material, or process parameter changes
- Comparability assessment planning for manufacturing changes that may affect potency, purity, glycosylation, or aggregate profile
- Process validation and PPQ readiness support for commercial-facing mAb manufacturing
- Continued process verification review using process and quality trend data across campaigns and lots
- Oversight of contamination control, viral safety strategy, and biologics manufacturing hygiene expectations
- QA support for tech transfer, site expansion, and late-stage manufacturing readiness
Batch Release Strategy & Product Quality Oversight
Release panel review, comparability packages, stability governance, and regulatory documentation for mAb lot disposition and lifecycle quality decisions.
- Batch release strategy for identity, purity, potency, safety, and product-related variant review
- Review of release packages for charge variants, glycan profile, aggregation, potency, and stability data
- Product quality review inputs for recurring trends, investigations, and lifecycle control updates
- Stability protocol oversight for drug substance and drug product across clinical and commercial stages
- Change impact review for specification updates, analytical method changes, or manufacturing shifts
- Support for regulatory documentation tied to BLA, MAA, and post-approval quality updates
- Quality review of reference standards, comparability protocols, and lifecycle control plans
- Disposition support for out-of-trend, atypical, or investigation-linked release decisions
Additional QA Capabilities
- Batch release strategy for identity, purity, potency, safety, and product-related variant review
- Review of release packages for charge variants, glycan profile, aggregation, potency, and stability data
- Product quality review inputs for recurring trends, investigations, and lifecycle control updates
- Stability protocol oversight for drug substance and drug product across clinical and commercial stages
- Change impact review for specification updates, analytical method changes, or manufacturing shifts
- Support for regulatory documentation tied to BLA, MAA, and post-approval quality updates
- Quality review of reference standards, comparability protocols, and lifecycle control plans
- Disposition support for out-of-trend, atypical, or investigation-linked release decisions
Comparability & Change Control
ICH Q5E-aligned comparability programs for manufacturing changes — from initial impact assessment and analytical panel design through protocol execution, data review, and regulatory package preparation.
Process Validation & CPV
Quality oversight for commercial process validation through PPQ execution and into continued process verification — providing monitoring frameworks that satisfy FDA's lifecycle validation expectations for biologics.
Batch Release & Disposition
Release framework design, batch record review, QC results integration, and disposition decision support — including atypical, OOT, and investigation-linked lot disposition for clinical and commercial supply.
Inspection Readiness
QA structure review, documentation gap assessment, and inspection preparation for FDA pre-approval inspections (PAI), routine GMP inspections, and CDMO quality audits — with specific focus on biologics manufacturing systems.
mAb QA Expertise Quality Assurance That Fits How mAb Programs Actually Work
Monoclonal antibody programs generate quality decisions at every stage — from the first cell bank qualification and clinical lot disposition through commercial process validation, ongoing monitoring, and post-approval change management. The quality systems that support these decisions need to be technically grounded, practically executable, and defensible to regulatory reviewers.
DES Pharma brings QA experience built directly from mAb development and manufacturing programs — across CDMOs, analytical laboratories, fill-finish operations, and regulatory submissions. We help sponsors build quality systems that hold up under inspection and scale with the program as it evolves from clinical to commercial.
- Comparability planning for cell line, process, site, and scale changes
- Batch release structures that integrate analytical, manufacturing, and stability review
- Stability governance for drug substance and drug product lifecycle decisions
- Process validation and continued process verification aligned with biologics operations
- Supplier and raw material quality systems for critical mAb manufacturing inputs
- Quality oversight that supports both compliance and practical execution
Why DES PharmaWhat We Bring to
Your mAb QA Program
QA expertise built from hands-on biologics manufacturing experience —
not just compliance checklists.
Biologics Manufacturing Grounding
Our QA consultants understand CHO manufacturing, Protein A purification, viral clearance, and fill-finish operations from the inside — enabling quality judgments that reflect manufacturing reality, not just regulatory text.
Comparability Expertise
Comparability is the most complex and highest-stakes QA activity in mAb lifecycle management. We bring specific expertise in change impact assessment, analytical panel design, ICH Q5E alignment, and regulatory package preparation.
Phase-Appropriate QA Design
We design quality systems that are appropriately rigorous for each development stage — preventing over-engineering in early clinical phases while ensuring the infrastructure is in place for commercial manufacturing and inspection.
Regulatory-Ready Documentation
Deviation reports, comparability protocols, validation summaries, and quality review packages are written for the reviewer — structured to support IND amendments, BLA modules, and post-approval supplements without major rework.
CDMO Quality Oversight
We help sponsors maintain meaningful quality oversight of contract manufacturers — from technical due diligence and quality agreement drafting through ongoing batch review, deviation escalation, and supplier performance monitoring.
Practical Execution Focus
Quality systems that are executable matter more than quality systems that look good on paper. We design QA frameworks that teams can actually operate — and we help calibrate those systems as programs grow and change.
Regulatory Framework Regulatory Standards Shaping mAb Quality Assurance
mAb QA programs operate within a layered regulatory framework spanning product standards, GMP requirements, comparability guidance, and lifecycle validation expectations. We help sponsors understand how these interact and build quality systems that satisfy them efficiently — without creating unnecessary procedural burden.
QA Lifecycle Milestones
Quality plan, cell bank qualification oversight, raw material qualification initiation, CDMO quality agreements
GMP batch release, deviation management, change control, stability program initiation
PPQ QA oversight, comparability packages, commercial release framework, PAI readiness
CPV governance, post-approval change management, annual PQR, lifecycle QA strategy
Regulatory Reference Framework
21 CFR 600
21 CFR 610
21 CFR 211.84
ICH Q5E
FDA Process Val
ICH Q10
Get Started Build a mAb QA Program That Holds Up Under Scrutiny
Whether you need phase-appropriate quality systems for early clinical supply or BLA-stage GMP readiness, our consultants are ready to assess your program and identify the right path forward.